Literature DB >> 33449170

Making sense of missense variants in TTN-related congenital myopathies.

Heinz Jungbluth1,2,3, Mathias Gautel4, Martin Rees1, Roksana Nikoopour1, Atsushi Fukuzawa1, Ay Lin Kho1, Miguel A Fernandez-Garcia2, Elizabeth Wraige2, Istvan Bodi5, Charu Deshpande6, Özkan Özdemir7,8, Hülya-Sevcan Daimagüler7,8, Mark Pfuhl1,9, Mark Holt1,9, Birgit Brandmeier1, Sarah Grover1, Joël Fluss10, Cheryl Longman11, Maria Elena Farrugia12, Emma Matthews13, Michael Hanna13, Francesco Muntoni14,15, Anna Sarkozy14, Rahul Phadke14, Ros Quinlivan14, Emily C Oates14,16,17, Rolf Schröder18, Christian Thiel19, Jens Reimann20, Nicol Voermans21, Corrie Erasmus22, Erik-Jan Kamsteeg23, Chaminda Konersman24, Carla Grosmann25, Shane McKee26, Sandya Tirupathi27, Steven A Moore28, Ekkehard Wilichowski29, Elke Hobbiebrunken29, Gabriele Dekomien30, Isabelle Richard31, Peter Van den Bergh32, Cristina Domínguez-González33, Sebahattin Cirak7,8,34, Ana Ferreiro35,36.   

Abstract

Mutations in the sarcomeric protein titin, encoded by TTN, are emerging as a common cause of myopathies. The diagnosis of a TTN-related myopathy is, however, often not straightforward due to clinico-pathological overlap with other myopathies and the prevalence of TTN variants in control populations. Here, we present a combined clinico-pathological, genetic and biophysical approach to the diagnosis of TTN-related myopathies and the pathogenicity ascertainment of TTN missense variants. We identified 30 patients with a primary TTN-related congenital myopathy (CM) and two truncating variants, or one truncating and one missense TTN variant, or homozygous for one TTN missense variant. We found that TTN-related myopathies show considerable overlap with other myopathies but are strongly suggested by a combination of certain clinico-pathological features. Presentation was typically at birth with the clinical course characterized by variable progression of weakness, contractures, scoliosis and respiratory symptoms but sparing of extraocular muscles. Cardiac involvement depended on the variant position. Our biophysical analyses demonstrated that missense mutations associated with CMs are strongly destabilizing and exert their effect when expressed on a truncating background or in homozygosity. We hypothesise that destabilizing TTN missense mutations phenocopy truncating variants and are a key pathogenic feature of recessive titinopathies that might be amenable to therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33449170      PMCID: PMC7882473          DOI: 10.1007/s00401-020-02257-0

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  60 in total

1.  POPS: A fast algorithm for solvent accessible surface areas at atomic and residue level.

Authors:  Luigi Cavallo; Jens Kleinjung; Franca Fraternali
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

2.  Titin-truncating mutations in dilated cardiomyopathy: the long and short of it.

Authors:  Diane Fatkin; Inken G Huttner
Journal:  Curr Opin Cardiol       Date:  2017-05       Impact factor: 2.161

3.  Titin Truncating Variants in Adults Without Known Congestive Heart Failure.

Authors:  James P Pirruccello; Alexander Bick; Mark Chaffin; Krishna G Aragam; Seung Hoan Choi; Steven A Lubitz; Carolyn Y Ho; Kenney Ng; Anthony Philippakis; Patrick T Ellinor; Sekar Kathiresan; Amit V Khera
Journal:  J Am Coll Cardiol       Date:  2020-03-17       Impact factor: 24.094

4.  Reply: Hereditary myopathy with early respiratory failure is caused by mutations in the titin FN3 119 domain.

Authors:  Stephan Lange; Lars Edström; Bjarne Udd; Mathias Gautel
Journal:  Brain       Date:  2014-02-24       Impact factor: 13.501

5.  A new titinopathy: Childhood-juvenile onset Emery-Dreifuss-like phenotype without cardiomyopathy.

Authors:  Rafael De Cid; Rabah Ben Yaou; Carinne Roudaut; Karine Charton; Sylvain Baulande; France Leturcq; Norma Beatriz Romero; Edoardo Malfatti; Maud Beuvin; Anna Vihola; Audrey Criqui; Isabelle Nelson; Juliette Nectoux; Laurène Ben Aim; Christophe Caloustian; Robert Olaso; Bjarne Udd; Gisèle Bonne; Bruno Eymard; Isabelle Richard
Journal:  Neurology       Date:  2015-11-18       Impact factor: 9.910

Review 6.  Increasing Role of Titin Mutations in Neuromuscular Disorders.

Authors:  Marco Savarese; Jaakko Sarparanta; Anna Vihola; Bjarne Udd; Peter Hackman
Journal:  J Neuromuscul Dis       Date:  2016-08-30

7.  Titin-truncating variants affect heart function in disease cohorts and the general population.

Authors:  Sebastian Schafer; Antonio de Marvao; Eleonora Adami; Lorna R Fiedler; Benjamin Ng; Ester Khin; Owen J L Rackham; Sebastiaan van Heesch; Chee J Pua; Miao Kui; Roddy Walsh; Upasana Tayal; Sanjay K Prasad; Timothy J W Dawes; Nicole S J Ko; David Sim; Laura L H Chan; Calvin W L Chin; Francesco Mazzarotto; Paul J Barton; Franziska Kreuchwig; Dominique P V de Kleijn; Teresa Totman; Carlo Biffi; Nicole Tee; Daniel Rueckert; Valentin Schneider; Allison Faber; Vera Regitz-Zagrosek; Jonathan G Seidman; Christine E Seidman; Wolfgang A Linke; Jean-Paul Kovalik; Declan O'Regan; James S Ware; Norbert Hubner; Stuart A Cook
Journal:  Nat Genet       Date:  2016-11-21       Impact factor: 38.330

8.  The crystal structure of the human titin:obscurin complex reveals a conserved yet specific muscle M-band zipper module.

Authors:  Stefano Pernigo; Atsushi Fukuzawa; Alessandro Pandini; Mark Holt; Jens Kleinjung; Mathias Gautel; Roberto A Steiner
Journal:  J Mol Biol       Date:  2014-12-06       Impact factor: 5.469

9.  Combination of Whole Genome Sequencing, Linkage, and Functional Studies Implicates a Missense Mutation in Titin as a Cause of Autosomal Dominant Cardiomyopathy With Features of Left Ventricular Noncompaction.

Authors:  Robert Hastings; Carin P de Villiers; Charlotte Hooper; Liz Ormondroyd; Alistair Pagnamenta; Stefano Lise; Silvia Salatino; Samantha J L Knight; Jenny C Taylor; Kate L Thomson; Linda Arnold; Spyros D Chatziefthimiou; Petr V Konarev; Matthias Wilmanns; Elisabeth Ehler; Andrea Ghisleni; Mathias Gautel; Edward Blair; Hugh Watkins; Katja Gehmlich
Journal:  Circ Cardiovasc Genet       Date:  2016-09-13

10.  Titin founder mutation is a common cause of myofibrillar myopathy with early respiratory failure.

Authors:  Gerald Pfeffer; Rita Barresi; Ian J Wilson; Steven A Hardy; Helen Griffin; Judith Hudson; Hannah R Elliott; Aravind V Ramesh; Aleksandar Radunovic; John B Winer; Sujit Vaidya; Ashok Raman; Mark Busby; Maria E Farrugia; Alec Ming; Chris Everett; Hedley C A Emsley; Rita Horvath; Volker Straub; Kate Bushby; Hanns Lochmüller; Patrick F Chinnery; Anna Sarkozy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-03-13       Impact factor: 10.154

View more
  5 in total

Review 1.  How Functional Genomics Can Keep Pace With VUS Identification.

Authors:  Corey L Anderson; Saba Munawar; Louise Reilly; Timothy J Kamp; Craig T January; Brian P Delisle; Lee L Eckhardt
Journal:  Front Cardiovasc Med       Date:  2022-07-04

2.  When is an obscurin variant pathogenic? The impact of Arg4344Gln and Arg4444Trp variants on protein-protein interactions and protein stability.

Authors:  Atsushi Fukuzawa; Daniel Koch; Sarah Grover; Martin Rees; Mathias Gautel
Journal:  Hum Mol Genet       Date:  2021-06-09       Impact factor: 6.150

3.  Solution NMR Structure of Titin N2A Region Ig Domain I83 and Its Interaction with Metal Ions.

Authors:  Colleen Kelly; Nicola Pace; Matthew Gage; Mark Pfuhl
Journal:  J Mol Biol       Date:  2021-03-31       Impact factor: 6.151

Review 4.  Protein Quality Control at the Sarcomere: Titin Protection and Turnover and Implications for Disease Development.

Authors:  Sebastian Kötter; Martina Krüger
Journal:  Front Physiol       Date:  2022-06-30       Impact factor: 4.755

5.  In Vitro Fertilization Using Preimplantation Genetic Testing in a Romanian Couple Carrier of Mutations in the TTN Gene: A Case Report and Literature Review.

Authors:  Bogdan Doroftei; Radu Maftei; Ovidiu-Dumitru Ilie; Theodora Armeanu; Maria Puiu; Iuliu Ivanov; Loredana Nemtanu
Journal:  Diagnostics (Basel)       Date:  2021-12-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.